Digital Content 
NEWS #PharmaBuzz
17 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/17/3189050/0/en/FDA-Accepts-Supplemental-New-Drug-Application-for-Arcutis-ZORYVE-roflumilast-Cream-0-3-for-the-Treatment-of-Plaque-Psoriasis-in-Children-Ages-2-to-5.html
13 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/13/3187274/0/en/Arcutis-Completes-Enrollment-in-INTEGUMENT-INFANT-Phase-2-Study-Evaluating-ZORYVE-roflumilast-Cream-0-05-in-Infants-with-Atopic-Dermatitis.html
04 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/04/3180240/0/en/Arcutis-Announces-Publication-of-Positive-Long-Term-Safety-and-Efficacy-Data-of-ZORYVE-roflumilast-Foam-0-3-in-Individuals-with-Seborrheic-Dermatitis-in-American-Journal-of-Clinica.html
30 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/30/3177307/0/en/Arcutis-Launches-ZORYVE-roflumilast-Cream-0-05-for-the-Treatment-of-Mild-to-Moderate-Atopic-Dermatitis-in-Children-Ages-2-to-5.html
30 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/30/3177526/0/en/Mother-Daughter-Duo-Tori-Spelling-and-Stella-McDermott-Partner-With-Arcutis-Biotherapeutics-in-the-Free-to-Be-Me-Campaign-Urging-People-With-Inflammatory-Skin-Conditions-to-Speak-W.html
28 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/28/3175418/0/en/Arcutis-Outlines-Strategy-for-Driving-Sustainable-Growth-and-Announces-Third-Quarter-2025-Financial-Results.html
Share 